Full Breakdown
Merck KGaA to Acquire Bio-Techne for $11.3 Billion
6/26/2026, 8:29:41 PM
Deal Overview
Merck KGaA announced an all-cash acquisition of Bio-Techne for $11.3 billion. The $73-per-share offer is a 24 % premium to the 24 June close and a 36 % premium to the one-month VWAP. Closing is expected in late 2026/early 2027.
Strategic Context
Merck’s M&A includes the 2014 Sigma-Aldrich purchase and the 2025 $3.9 billion SpringWorks Therapeutics deal. The firm aims to make its Life Sciences unit, which posted €8.98 billion in 2025, its main growth driver and reduce reliance on pharmaceuticals.
Companies and Leadership
Merck KGaA is led by CEO Kai Beckmann (May 2025) and Life Sciences head Jean-Charles Wirth. Bio-Techne’s board chair is Robert V. Baumgartner; its President and CEO is Kim Kelderman. Analyst Puneet Souda of Leerink Partners has weighed in.
Deal Terms and Financial Highlights
Merck will pay $73 per share in cash, financed with €2.74 billion cash and debt. The deal targets €140 million of cost synergies by year three. Bio-Techne posted $1.22 billion in FY 2025 sales, with consumables 81 % of revenue. Merck’s addressable market for advanced tools is $27 billion, including a $5 billion cell-and-gene-therapy segment growing >20 % annually.
Anticipated Strategic Impact
Bio-Techne contributes roughly 6,000 proteins, 425,000 antibodies and platforms for multi-omics, spatial biology and cell-therapy manufacturing. Merck expects the combined portfolio to extend its reach from discovery to commercial manufacturing and add EBITDA-margin accretion.
Official Statements
Merck called the deal “a milestone toward delivering on our mid-to-long-term strategic agenda” and praised Bio-Techne’s “recognised portfolio of cytokines, growth factors, antibodies and immunoassay kits.” Jean-Charles Wirth called the catalog a “big, big plus” and noted a $27 billion market opportunity. Kelderman said it will bring “greater scale and expanded capabilities to accelerate innovation.”
Criticism and Valuation Concerns
Analyst Puneet Souda says the 24 % premium undervalues Bio-Techne, citing an implied EV/EBITDA multiple of 26 × versus 16 × for peers. Matt Larew of William Blair called the price “a bit disappointing,” noting that cost savings, not revenue synergies, drive the upside.
Conflicting Figures and Gaps
Sources differ on the premium—24 % to the close versus 36 % to the one-month VWAP—and on Beckmann’s start date (May or September 2025). The timeline for cost-synergy realization and regulatory review remains unclear.
Verbatim Quotes
- “This transaction is an important milestone toward delivering on our mid- to long-term strategic agenda,” — Kai Beckmann, CEO, Merck KGaA
- “Bio-Techne is an outstanding fit that directly supports our strategic direction focused on delivering cutting-edge products and solutions across the entire industry value chain—from lab customers to those manufacturing in the biotech and pharmaceutical industries,” — Kai Beckmann, Merck KGaA
- “As part of Merck, we will have greater scale and expanded capabilities to accelerate innovation and deepen our impact.” — Kim Kelderman, CEO, Bio-Techne
- “We see the acquisition multiple undervaluing what is a highly accretive asset in our view,” — Puneet Souda, Leerink Partners
Outlook
Merck targets early 2027 for closing, after which it will integrate Bio-Techne’s products and pursue €140 million in cost synergies. The deal is positioned as a catalyst for further consolidation in the life-sciences tools market.
